Investigation announced for Investors in shares of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) over potential Wrongdoing

An investigation was announced over potential breaches of fiduciary duties by certain directors at Harmony Biosciences Holdings, Inc.

Investors who purchased shares of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Harmony Biosciences Holdings, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

Plymouth Meeting, PA based Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. Harmony Biosciences Holdings, Inc. reported that its annual Total Revenue rose from $305.44 million in 2021 to $437.85 million in 2022, and that its Net Income increased from $34.59 million in 2021 to $181.46 million in 2022.

On March 28, 2023, before the market opened, market analyst Scorpion Capital published a report on Harmony Biosciences Holdings, Inc.. The report alleged, among other things, that Harmony's drug, Wakix (pitolisant), is unsafe and causes heart-related issues (including sudden cardiac death) to occur in patients who are otherwise healthy. The report further alleged that, to obtain approval for Wakix from the United States Food & Drug Administration ("FDA"), Harmony Biosciences obtained approval in foreign nations with allegedly lax drug safety controls, such as Russia, before tricking the FDA into approving the drug based on the prior approvals. The report also alleged that the company engaged in kickback schemes to pay physicians to use its drugs, has a sham patent portfolio, and engages in false advertising.

Shares of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) declined to as low as $29.81 per share on March 28, 2023.

Those who purchased shares of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.